- Home
- DXCM vs PODD Comparison
DXCM vs PODD Comparison
Compare DXCM & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXCM | PODD |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 22.1B |
| IPO Year | 2005 | 2007 |
Fundamental Metrics
Financial Performance| Metric | DXCM | PODD |
|---|---|---|
| Price | $67.51 | $288.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 19 |
| Target Price | $86.86 | ★ $366.58 |
| AVG Volume (30 Days) | ★ 4.7M | 688.4K |
| Earning Date | 02-12-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.75 | N/A |
| EPS | 1.80 | ★ 3.45 |
| Revenue | ★ $4,515,900,000.00 | $2,521,800,000.00 |
| Revenue This Year | $17.38 | $32.55 |
| Revenue Next Year | $12.76 | $20.50 |
| P/E Ratio | ★ $37.61 | $83.64 |
| Revenue Growth | 14.21 | ★ 27.11 |
| 52 Week Low | $54.11 | $230.05 |
| 52 Week High | $93.25 | $354.88 |
Technical Indicators
Market Signals| Indicator | DXCM | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 59.98 | 38.03 |
| Support Level | $65.56 | $285.02 |
| Resistance Level | $67.95 | $292.75 |
| Average True Range (ATR) | 1.80 | 7.04 |
| MACD | 0.08 | -0.24 |
| Stochastic Oscillator | 61.35 | 18.30 |
Price Performance
Historical ComparisonAbout DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.